business
Lilly’s new experimental shot produced 28% weight loss
The injection is different than Zepbound and Foundayo.
Read full story on MarketWatch → More top storiesAlso covered by
NY Times
Experimental Drug Yields Dramatic Weight Loss
CNBC
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
STAT News
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Healthline
‘Next-Gen’ GLP-1 Leads to 16% More Weight Loss. Is It Better Than Zepbound?
Aggregated and edited by the Scoop newsroom. We surface news from MarketWatch alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop